[3S] Protein Synthesis Inhibitors Flashcards
(131 cards)
1
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Widely distributed to all tissues including the CNS/CSF and placenta
A
Chloramphenicol
2
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Chloramphenicol excretion
A
Renal; partly bile and feces
3
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Chloramphenicol ROA
A
IV
4
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● Binds to 50S
● Inhibits peptide bond formation
● Drug interactions: Phenytoin, Tolbutamide, Chlorpropamide, Warfarin
A
Chloramphenicol
5
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Bacteriostatic
● Gr(+) aerobes
● Gr(+) anaerobes
● Gr(-) aerobes
● Gr(-) anaerobes
● Rickettsiae
A
Chloramphenicol
6
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Especially effective against:
● H. influenzae
● N. meningitidis
● Bacteroides
A
Chloramphenicol
7
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Inactive: Chlamydia
A
Chloramphenicol
8
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
GI disturbances & Oral or Vaginal Candidiasis
A
Chloramphenicol Tetracycline & Doxycycline
9
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Bone marrow: Inhibition of red cell maturation
● Aplastic anemia
● Gray Baby Syndrome
A
Chloramphenicol
10
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Absorption is affected by food
A
Tetracycline
11
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Tetracycline excretion
A
Renal & Biliary
12
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Tetracycline ROA
A
PO
13
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● Bacteriostatic
● Bind to 30S
● Inhibits binding of aminoacyl-tRNA to the acceptor site
● Intracellular concentration
A
ALL Tetracyclines
14
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
H. pylori ulcers
A
Tetracycline
15
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Gram-positive and gram- negative + anaerobes
● Chlamydiae
● Mycoplasma pneumoniae
● Borrelia, spirochetes, Anaplasma phagocytophilum, Ehrlichia sp.
A
Tetracycline
16
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Mainly for ricketssiae (Rocky mountain spotted fever) and borrelia (Lyme disease)
A
Tetracycline
17
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Alters intestinal flora
● Esophageal ulceration
● Enterocolitis
A
Tetracycline & Doxycycline
18
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Bacterial superinfections (S. aureus, C. difficile)
● Bones and teeth damage: Enamel dysplasia Crown
deformation
● Hepatic toxicity
● Renal toxicity
A
Tetracyclin, Doxycycline & Demeclocycline
19
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Fanconi Syndrome
A
Tetracycline & Doxycycline
20
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Renal tubular acidosis
● Nephrotoxicity
● Exacerbate pre-existing renal dysfunction
A
Tetracycline & Doxycycline
21
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Absorption is not affected by food
A
Doxycycline & Minocycline
22
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Doxycycline ROA
A
PO/IV
23
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Lyme disease
A
Tetracycline & Doxycycline
24
Q
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Malaria prophylaxis
A
Doxycycline
25
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Amoebiasis
Doxycycline
26
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Primary & secondary syphilis (penicillin allergy)
Doxycycline
27
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Vestibulotoxicity
Doxycycline
28
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Demeclocycline excretion
Biliary & renally
29
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Demeclocycline ROA
PO
30
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Off-label treatment for inappropriate secretion of antidiuretic hormones
Demeclocycline
31
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
ADH-secreting tumors
Demeclocycline
32
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Photosensitivity (UV Light)
Demeclocycline
33
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Minocycline excretion
Mostly fecal
34
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Minocycline ROA
PO/IV
35
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Meningococcal carrier state
Minocycline
36
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS: Minocycline
____________ is preferred due to resistant cases
ciprofloxacin/rifampin
37
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Vestibular toxicity
● Exacerbate pre-existing renal dysfunction
Minocycline
38
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Tigecycline excretion
Nonrenal (biliary)
39
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Longest half-life
Tigecycline
40
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● MDR organisms
● Treats skin and skin-structure infections, intra- abdominal infections and CAP
Tigecycline
41
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Tigecycline ROA
IV
42
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Gr(+)
o CoNS, MRSA, VRE, Strep, Enterococci,
● Gr(-)
o Enterobacteriaceae, MDR Acinetobacter, Chlamydia, L. pneumophilia
Tigecycline
43
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Anaerobes, ricketssiae, mycobacteria
Tigecycline
44
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
INACTIVE AGAINST: Proteus, Providencia, Pseudomonas
Tigecycline
45
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Nausea
● Significantly higher mortality rates
Tigecycline
46
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Eravacycline excretion
Bile & urine + feces (10-40%)
47
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Eravacycline ROA
IV
48
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● MDR organisms
● Complicated intra-abdominal infections
● Tigecycline uses
Eravacycline
49
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
NOT effective against UTI
Eravacycline
50
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Tetracycline toxicities + dose adjusted if used alongside CYP3A inducers like rifampin
Eravacycline
51
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Omadacycline excretion
Bile
52
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Administered 4 hours after as these may decrease
before or meals/supplements absorption
Omadacycline
53
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Omadacycline ROA
PO/IV
54
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Unaffected by most common resistance mechanisms
Omadacycline
55
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Can treat bacterial pneumonia and acute bacterial skin/skin- structure infections
● Tigecycline uses
Omadacycline
56
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Tetracycline toxicities + Rarer esophageal ulcerations
Omadacycline
57
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Streptomyces erythraea
Macrolides: Erthryomycin
58
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Erythromycin excretion
Biliary; partly renal
59
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Food interferes with absorption
Macrolides: Erthryomycin
60
Erthryomycin ROA
PO/IV
61
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
50S inhibitor; inhibits peptide bond formation
Macrolides: Erthryomycin & Fidaxomicin
62
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Prototype drug
Macrolides: Erthryomycin
63
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● GR(+)
o pneumococci, strep, staph, corynebacteria, Mycoplasma, Legionella, Chlamydia, H. pylori, Listeria, Mycobacteria
● GR(-)
o Bordetella, Rickettsia, Campylobacter
Macrolides: Erthryomycin
64
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Corynebacterial
o sepsis, erythrasma
● Neisseria, Bartonella, Treponema, diphtheria,
● CAP
o Mycoplasma, Legionella, Pneumococci
Macrolides: Erthryomycin
65
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Prophylaxis : dental endocarditis
Macrolides: Erthryomycin
66
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Off-label : Gastroparesis
Macrolides: Erthryomycin
67
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Vestibular toxicity
● Exacerbate pre-existing renal dysfunction
Macrolides: Erthryomycin
68
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Clarithromycin excretion
Metabolized in the liver, partially excreted through urine
69
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Clarithromycin ROA
PO
70
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● 50S inhibitor; inhibits peptide bond formation
● Also inhibits CYP3A4 and drug efflux pumps
Macrolides: Clarithromycin
71
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Mycobacterium avium complex
● M. leprosae
● T. gondii
● H. influenzae
Macrolides: Clarithromycin
72
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Similar toxicities and interactions as erythromycin
● Lower incidence gastrointestinal intolerance
Macrolides: Clarithromycin
73
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Torsades de pointes
● Arrhythmia
Macrolides: Clarithromycin & Azithromycin
74
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Azithromycin excretion
Bile & urine (remaining)
75
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Azithromycin ROA
PO
76
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● 50S inhibitor; inhibits peptide bond formation
● 15-atom ring unlike the usual 14; cannot deactivate CYP450
Macrolides: Azithromycin
77
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Mycobacterium avium complex
● T. gondii
● H. influenzae
● Chlamydia sp.
Macrolides: Azithromycin
78
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Less active
● Staphylococci
● Streptococci
Macrolides: Azithromycin
79
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Possible increased risk of cardiac death
Macrolides: Azithromycin
80
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Fidaxomicin excretion
Feces & urine (remaining)
81
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Fidaxomicin ROA
PO
82
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Clostridioides difficile
● Gr(+) aerobes
● Gr(-) anaerobes
Macrolides: Fidaxomicin
83
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Clindamycin excretion
Metabolized in the liver; excreted through bile & urine
84
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Clindamycin ROA
PO
85
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Streptomyces lincolnensis
Lincosamide: Clindamycin
86
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Gr(+) cocci
● Streptococci & Staphylococci
o Skin and soft tissue infections
Lincosamide: Clindamycin
87
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Pneumococci, Bacteroides sp.
● Other anaerobes : Bacteroides, Fusobacterium, Prevotella
o Severe anaerobic infections
Lincosamide: Clindamycin
88
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Toxic shock syndrome (with penicillin G)
● Necrotizing fasciitis
Lincosamide: Clindamycin
89
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Wounds of the abdomen and gut (with ________ or __________)
cephalosporins or aminoglycosides ; Lincosamide: Clindamycin
90
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Female genital tract: Septic abortion, Pelvic abscesses, Pelvic inflammatory disease
Lincosamide: Clindamycin
91
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Lung and peritoneal abscesses
● Endocarditis prophylaxis (valvular disease)
Lincosamide: Clindamycin
92
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
AIDS:
o P. jiroveci pneumonia (with primaquine)
o Toxoplasmosis (with pyrimethane)
Lincosamide: Clindamycin
93
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● GI irritation
● Mainly diarrhea
● Skin rashes
● Neutropenia
Lincosamide: Clindamycin
94
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Hepatic dysfunction
● Pseudomembranous colitis (superinfections with C. difficile)
Lincosamide: Clindamycin
95
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Ketolides: Telithromycin
96
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Telithromycin excretion
Metabolized in the liver and excreted through bile and urine
97
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Telithromycin ROA
PO
98
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● CAP
● Macrolide-resistant bacteria
Ketolides: Telithromycin
99
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Hepatitis
● Liver failure
● Myasthenia gravis (contraindication)
Ketolides: Telithromycin
100
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● STIs
● macrolide-resistant bacteria
Ketolides: Solithromycin
101
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Adverse effects are inadequately observed
Ketolides: Solithromycin
102
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Solithromycin excretion
Feces
103
MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Solithromycin ROA
PO/IV
104
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Quinupristin-dalfopristin elimination
Feces
105
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Quinupristin-dalfopristin ROA
IV
106
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● Rapidly bactericidal
● 50S inhibitor; inhibits peptide bond formation
Streptogramins: Quinupristin-dalfopristin
107
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
Gr(+)
o MDR strep, PRSP, methicillin-susceptible and resistant staph, E. faecium
Streptogramins: Quinupristin-dalfopristin
108
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Not rapidly bactericidal against E. faecium
● Not active against E. faecalis
Streptogramins: Quinupristin-dalfopristin
109
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Arthralgia-myalgia syndrome
● Pain at infusion site
Streptogramins: Quinupristin-Dalfopristin
110
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
CYP3A4 inhibitor - increases concentrations of warfarin, diazepam, quetiapine, simvastatin, and cyclosporine
Streptogramins: Quinupristin-Dalfopristin
111
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Linezolid elimination
Urine
112
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● 50S inhibitor; inhibits peptide bond formation
● Binds at the 23S ribosomal RNA of the 50S subunit
Oxazolidinones: Linezolid & Tedizolid
113
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● MRSA
● VRE
● HCAP
● CAP
● [Off-label] MDR-TB, Nocardia
Oxazolidinones: Linezolid
114
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Hematologic effects (thrombocytopenia, neutropenia, anemia)
Oxazolidinones: Linezolid
115
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Optic and peripheral neuropathy
● Lactic acidosis
Oxazolidinones: Linezolid
116
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Serotonin syndrome (with SSRIs)
Oxazolidinones: Linezolid
117
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Linezolid ROA
PO/IV
118
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Staphylococci - better than linezolid
● Skin and soft tissue infections
Oxazolidinones: Tedizolid
119
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Nausea, dizziness, diarrhea
● Lower risk of hematologic effects, bone marrow suppression, and serotonin syndrome
Oxazolidinones: Tedizolid
120
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Lefamulin excretion & metabolism
Feces, partly urine
121
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Lefamulin ROA
PO/IV
122
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Tedizolid ROA
PO/IV
123
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS
Tedizolid excretion
Feces & urine (remaining)
124
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA
● Binds to 50S
● Prevents bacterial tRNA from binding appropriately by binding pocket
Pleuromutilins: Lefamulin
125
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
CAP pathogens
o Legionella, Mycoplasma, Chlamydophila
Pleuromutilins: Lefamulin
126
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
● Aerobic Gr (+)
o S. pyogenes, S. aureus, E. faecium
● STI
o M. genitalium, Neisseria, Chlamydia
Pleuromutilins: Lefamulin
127
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
NO ACTIVITY against E. faecalis
o Pseudomonas, Acinetobacter, Enterobacteriaceae
Pleuromutilins: Lefamulin
128
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
● Infusion-site reactions
● GI disturbances
Pleuromutilins: Lefamulin
129
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES
Congenital malformations (contraindicated during pregnancy)
Pleuromutilins: Lefamulin
130
BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS
Doxycycline elimination
Nonrenally
131
NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS
High potency against Gr(+) bacteria
○ MRSA
○ VRE
○ Streptococci
○ Gr(+) anaerobesg
Oxazolidinones: Tedizolid
